Clinical Trials Search Results - National Cancer Institute

Clinical Trials Search Results - National Cancer Institute

CANCER TREATMENT

• Types of Treatment
• Side Effects
• Clinical Trials Information for Patients and Caregivers
  • Find NCI-Supported Clinical Trials
    • How to Join a Cancer Clinical Trial
    • Help With Clinical Trials Search
  • What Are Clinical Trials?
  • Paying for Clinical Trials
  • Patient Safety
  • Deciding to Take Part in a Trial
  • Questions to Ask about Treatment Clinical Trials
  • Selected NCI-Supported Trials
• A to Z List of Cancer Drugs
• Complementary & Alternative Medicine (CAM)
• Questions to Ask about Your Treatment
• Research

101.

Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: GOG-0263, NCI-2011-02037, CDR0000670125, NCT01101451

102.

Acupuncture in Treating Dry Mouth Caused by Radiation Therapy in Patients with Head and Neck Cancer

Status: Active
Phase: Phase III
Type: Supportive care
Age: Not specified
Trial IDs: MDA-04-01, NCI-2011-02073, CDR0000674208, WFU 97115, WF-97115, NCT01141231

103.

Lenalidomide or Observation in Treating Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E3A06, NCI-2011-02057, CDR0000682012, ECOG-E3A06, NCT01169337

104.

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8109-002, NCI-2011-00940, EC-FV-06, NCT01170650

105.

Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930

106.

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 113676, NCI-2012-01195, NCT01200589

107.

Yoga or Stretching and Relaxation in Improving Physical Function in Patients with Stage 0-III Breast Cancer Undergoing Radiation Therapy

Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 2009-0976, NCI-2012-01895, NCT01202851

108.

Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662

109.

Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1011, NCI-2011-02604, CDR0000686574, SWOG-S1011, NCT01224665

110.

Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma

Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906

111.

Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412

112.

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Status: Active
Phase: Phase III
Type: Treatment
Age: Over 18
Trial IDs: ENGOT-EN2-DGCG/EORTC55102, NCI-2014-00983, 2010-023081-52, NCT01244789

113.

PEG-Interferon Alfa-2a or Hydroxyurea in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MPD-RC 112, NCI-2012-00269, NCT01259856

114.

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 72
Trial IDs: CS001P3, NCI-2014-01668, 2010-019952-35, NCT01265849

115.

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer

Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037

116.

A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB08026, NCI-2011-03815, NCT01280565

117.

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

Status: Temporarily closed
Phase: Phase III
Type: Supportive care
Age: 6 months to 21 years
Trial IDs: ACCL0934, NCI-2011-02636, CDR0000695661, COG-ACCL0934, NCT01371656

118.

Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 3 months to 30 years
Trial IDs: ACCL0933, NCI-2011-02640, CDR0000695748, COG-ACCL0933, NCT01307579

119.

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PIX306 (PIX-R Trial), NCI-2012-00808, PIX306, NCT01321541

120.

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669

121.

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer

Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881

122.

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588

123.

Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981

124.

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: HCC-P3-11-01, NCI-2011-03569, NCT01387932

125.

Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756